.Pharmacolibrary.Drugs.C_CardiovascularSystem.C09A_AceInhibitorsPlain.C09AA03_Lisinopril.Lisinopril

Information

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor used primarily for the treatment of hypertension, heart failure, and post-myocardial infarction. It is an oral medication approved and widely used in clinical practice today.

Pharmacokinetics

Pharmacokinetic parameters are reported for healthy adult volunteers after single oral administration.

References

1. Sandra, L, et al., & Vermeulen, A (2024). Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney function. British journal of clinical pharmacology 90(2) 504–515. DOI:10.1111/bcp.15936 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37864281

2. Winnicki, W, et al., & Sengoelge, G (2012). Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. European journal of clinical investigation 42(10) 1087–1093. DOI:10.1111/j.1365-2362.2012.02699.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22845880

3. Trachtman, H, et al., & Patel, UD (2015). Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection. Clinical pharmacology and therapeutics 98(1) 25–33. DOI:10.1002/cpt.127 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25807932

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)